← All trials
NCT01825200
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2013
- Primary completion
- May 1, 2013
- Completion date
- May 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 2640
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Protein Sciences CorpLead sponsor
- MRA Clinical ResearchOverall official - principal investigator
- Benchmark ResearchOverall official - principal investigator
- Regional Clinical ResearchOverall official - principal investigator
- Clinical Research of South FloridaOverall official - principal investigator
- Research Across AmericaOverall official - principal investigator
- Clinical Research Center of Nevada, LLCOverall official - principal investigator
- Genova Clinical ResearchOverall official - principal investigator
- Rapid Medical Research, Inc.Overall official - principal investigator
- Heartland Research Associates, LLCOverall official - principal investigator
- Wake Forest UniversityOverall official - principal investigator
- Meridien ResearchOverall official - principal investigator
- Maine Research AssociatesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.